Paris (France) and Tokyo (Japan), February 14, 2024 Iktos, a company specialized in Artificial Intelligence for new drug design, announces the opening of Iktos K.K., its new subsidiary in Japan....
Iktos announces the appointment of Avirup Bose as Chief Business Officer Paris (France), 18 January, 2024 “ Iktos, a company specialized in Artificial Intelligence for new drug design, announces...
Iktos and Bayer Announce Collaboration to expand the use of Artificial Intelligence to Design New Sustainable Crop Protection Solutions Paris, France, December 14, 2023 “ Iktos, a company specialized...
Paris, France, July 3, 2023 – Iktos, a company specialized in Artificial Intelligence for new drug design, today announced that Kissei Pharmaceutical Co., Ltd. (“Kissei”), a Japanese pharmaceutical company with approximately 75 years of history, specialized in the field of urology, kidney-dialysis and unmet medical needs, has introduced Makya™, Iktos Software as a Service Platform for AI-driven drug discovery. This will enable the rapid and efficient design of new small molecules, leading to an increase in the speed of drug discovery and development.
Kissei introduces Iktos AI Drug Discovery System Paris, France, July 3, 2023Iktos, a company specialized in Artificial Intelligence for new drug design, today announced that Kissei Pharmaceutical...
PARIS--(BUSINESS WIRE)--Iktos, a company specialized in Artificial Intelligence for new drug design and Curreio, Inc. (Curreio), a Japanese company specializing in structural analysis of biomolecules using cryo-electron microscopy, today announced a collaboration agreement in AI for new drug design. In this collaboration, Iktos’ de novo generative design technology in combination with Curreio’s state-of-the-art cryo-EM platform will be used to facilitate the rapid and cost-effective design of novel preclinical drug candidates for an undisclosed target.
PARIS and LAUSANNE Switzerland, March 9, 2023 /PRNewswire/ -- Iktos, a company specializing in artificial intelligence for new drug discovery, today announces the closing of a € 15.5m Series A financing co-led by new investors M Ventures and Debiopharm Innovation Fund with participation from Omnes Capital.
PARIS--(BUSINESS WIRE)--Iktos, a leader in Artificial Intelligence for new drug design, today announced a collaboration with Medicines for Malaria Venture (MMV), a leading product development partnership (PDP) in the field of antimalarial drug research and development. Under this collaboration agreement, Iktos will apply its new ‘DockAI’ technology to expedite the discovery of novel antimalarial drug candidates.
PARIS--(BUSINESS WIRE)--Iktos, a company specialized in Artificial Intelligence for new drug design, today announced a collaboration with Galapagos, a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, to apply Iktos’s generative modelling artificial intelligence (AI) technology in one of Galapagos drug discovery programs. Under the agreement, Iktos will apply its de novo ligand and structure-based generative modelling technologies and software Makya™, its AI-based retrosynthesis analysis and planning tool Spaya™, and its know-how in computational drug design to expedite the identification of potential pre-clinical candidates and to identify additional novel chemical matter with suitable properties. Galapagos scientists will benefit from direct access to Makya™ and Spaya™ as part of the collaboration.
PARIS--(BUSINESS WIRE)--Iktos, a company specialized in Artificial Intelligence for new drug design, today announced a research collaboration with Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company changing lives with innovative peptide-based medicines to co-develop generative and predictive AI technologies for peptide drug design.